Leonard Lichtenfeld, MD: Recently, the FDA went into a new model—what they called the Oncology Center of Excellence—and they have agreed to do that, and they’re moving forward with it. I will say that I was involved in some of those discussions. The American Cancer Society supported it, and so did a number of other cancer advocacy organizations and influential individuals.
In the cancer space, most of us feel the FDA has tried to be as responsive as possible. I know everyone doesn’t agree with that, but they’ve tried to be as responsible as possible to get new drugs through the pipeline when appropriate, and they’ve revised their rules. They’re looking at smaller populations of patients. They’re not requiring randomized trials when there’s a clear unmet need and we have a drug that really works. They have really worked much quicker than was the case in the past.
Our hope is that, with this new Oncology Center of Excellence, the FDA is going to do even better, because when you talk to the folks at the FDA you learn that some experts are over here, some experts may be in a different place, and the lines of responsibility are getting blurred.
So, you may have a biologic medication that would be tested in lung cancer, but the tests to see if a patient is eligible for that medicine are over in a different department, and maybe a device needs to be approved and that’s in a different department. By bringing that together and hopefully streamlining the process, we’ll all be better off. Having said that—and I don’t mean this negatively—the reality is that it’s a government agency. So, making this happen is going to take a lot of effort on the part of a lot of people. But we, the American Cancer Society, think that it’s a step in the right direction.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More